Wird geladen...
Can rituximab be used in the treatment of pemphigus vulgaris during the COVID‐19 pandemic?
Rituximab is a monoclonal antibody that targets CD20, a B‐lymphocyte antigen; that leads to a decline in the B‐cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpaşa Medical Faculty w...
Gespeichert in:
| Veröffentlicht in: | Dermatol Ther |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Inc.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7883057/ https://ncbi.nlm.nih.gov/pubmed/33296557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.14647 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|